CIVCO Releases New Non-Invasive Solution for Head and Brain Tumors2/27/2013
CIVCO Medical Solutions, the leading provider of radiation oncology motion management solutions, announced the release of trUpoint ARCHTM, a new stereotactic radiosurgery (SRS) and stereotactic fractionated radiation (SRT) solution for head and brain tumors.
Stereotactic radiosurgery involves delivering very high doses of radiation quickly, using precisely shaped beams that focus on the tumor and minimize exposure of surrounding healthy tissues and organs. trUpoint ARCH is a frameless solution designed to effectively stabilize a patient’s head in a non-invasive, comfortable hold for delivering the high radiation doses.
“trUpoint ARCH is a solution that produces repeatable results for radiosurgery patients requiring absolute positioning. Our focus when developing new patient positioning and immobilization products is patient comfort and ease of set-up for the clinician; this solution delivers both,” said Nat Geissel, senior vice president and general manager of CIVCO’s radiation oncology business unit.
The trUpoint ARCH system provides clinicians a simple and manageable patient set-up assuring accuracy and repeatability during SRS and SRT treatments. Indexing is available on the device, nasion, and the arch design allows flexibility in treatment planning around the device. Compatible with CIVCO’s Universal Couchtop™, Posifix® thermoplastic system, AccuForm™ cushions and Protura™ Robotic Patient Positioning System, trUpoint ARCH provides a comprehensive motion management solution for effective SRS/SRT treatment.
The first cancer center to benefit from this innovative solution is the University Hospital Zurich, Switzerland. They began using trUpoint ARCH with their radiosurgery program in late January 2013.